Гемолитико-уремический синдром, ассоциированный с шига-токсин-продуцирующей Esherichia соїі

Значительный прогресс в понимании природы этого заболевания в последнее десятилетие позволяет говорить о гемолитико-уремическом синдроме как о гетерогенной группе заболеваний, относящихся к одному классу тромботических микроангиопатий, характеризующихся различной этиологией и патогенезом. Представленный обзор посвящен наиболее распространенной форме гемолитико-уремическом синдрома, ассоциированного с шига- токсин-продуцирующей E.coli (STEC-ГУС). Обобщены последние данные, касающиеся этиологии, патогенеза и терапии типичного гемолитико-уремического синдрома с акцентом на механизмы реализации патологического процесса и новые подходы к терапии.

гемолитико-уремический синдром, тромботическая микроангиопатия, шига-токсин, гемолитическая анемия, тромбоцитопения, острое повреждение почек

1. Karmali M.A., Petric M., Lim C. et al. Escherichia coli cytotoxin., haemolytic-uraemic syndrome., and haemorrhagic colitis. Lancet. 1983; 3;2(8362):1299-1300

2. Noris M., Mescia F., Remuzzi G. STEC-HUS., atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012; 8(11): 622-633

3. Scheiring J., Andreoli Sh.P., Zimmerhackl L.B. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS) Pediatr Nephrol. 2008; 23: 1749-1760

4. Johnson S., Taylor C.M. What’s new in hemolytic uremic syndrome. Eur J Pediatr. 2008. 167: 965-971

5. Besbas N., Karpman D., Landau D. et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney International. 2006. 70: 423-431

6. Loirat C., Fakhouri F., Ariceta G. et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15-39

7. Constantinescu A.R., Bitzan M., Weiss L.S. et al. Non-entero-pathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis. 2004; 43: 976-982

8. Sonntag A.K., Prager R. et al. Phenotypic and genotypic analyses of enterohemorrhagic Escherichia coli O145 strains from patients in Germany. J Clin Microbiol. 2004; 42: 954-962

9. Ruggenenti P., Noris М., Remuzzi G. Thrombotic microangiopathy., hemolytic uremic syndrome., and thrombotic thrombocytopenic purpura. Kidney International. 2001. 60: 831-846

10. Loirat C., Taylor C.M. Hemolytic Uremic Syndromes. In: Pediatric Nephrology., 4th ed., Avner E.D., Harmon W.E., Niaudet P. (Eds)., Lippincott., Williams & Wilkins., Baltimore 2004:887

11. Lynn R.M., O’Brien S.J., Taylor C.M. et al. Childhood hemolytic uremic syndrome United Kingdom and Ireland Emerg Infect Dis. 2005; 11: 590-596

12. Tarr P.I., Gordon C.A., Chandler W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073-1086

13. Molbak K., Mead P.S., Griffin P.M. Antimicrobial therapy in patients with Escherichia coli O157:H7 infection. JAMA. 2002; 288(8):1014-1016

14. Gerber A., Karch H. et al. Clinical Course and the Role of Shiga Toxin Producing Escherichia coli infection in the haemolytic uraemic syndrome in pediatric patients., 1997-2000 in Germany and Austria: a prospective study. J Infect Dis. 2002; 186:493-500

15. Bielaszewska M., Kock R., Friedrich A.W. Shiga Toxin-Mediated Hemolytic Uremic Syndrome: Time to Change the Diagnostic Paradigm? PLoS ONE. 2007. 10. e1024

16. Mellmann A., Bielaszewska M. et al. Enterohemorrhagic Escherichia coli in human infection: in vivo evolution of a bacterial pathogen. Clin Infect Dis. 2005; 41:785-792

17. Zimmerhackl L.B., Rosales A. et al. Enterohemorrhagic Escherichia coli O26:H11-Associated Hemolytic Uremic Syndrome: Bacteriology and Clinical Presentation. Semin Thromb Hemost. 2010; 36(6): 586-593

18. Zhang W., Mellmann A. et al. Structural and functional differences between disease-associated genes of enterohaemorrhagic Escherichia coli O111. Int J Med Microbiol. 2007; 297: 17-26

19. Vaillant V., Espié E., de Valk H et al. Undercooked ground beef and person-to-person transmission as major risk factors for sporadic hemolytic uremic syndrome related to Shiga-toxin producing Escherchia coli infections in children in France. Pediatr Infect Dis J 2009; 28:650

20. Friedrich Alexander W., Zhang W., Bielaszewska M et al. Prevalence., virulence profiles., and clinical significance of Shiga toxin negative variants of enterohemorrhagic Escherichia coli O157 Infection in Humans. Clinical Infectious Diseases 2007; 45:39-45

21. Butler T. Haemolytic uraemic syndrome during shigellosis. Trans R Soc Trop Med Hyg. 2012; 106(7):395-399

22. Taylor С.М. Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome. Pediatr Nephrol. 2008; 23:1425-1431

23. Mbonu C.C., Davison D.L., El-Jazzar K.M. et al. Clostridium difficile colitis associated with hemolytic-uremic syndrome. Am J Kidney Dis. 2003; 41(5):14

24. Ruggenenti P., Remuzzi G.E. coli O104:H4 German outbreak: a missed opportunity» Piero Ruggenenti and Giuseppe Remuzzi. Nat. Rev. Nephrol. 2012. 8., 558-560

25. Scheutz F. et al. Characteristics of the enteroaggregative Shiga toxin/verotoxin-producing Escherichia coli O104:H4 strain causing the outbreak of haemolytic uraemic syndrome in Germany., May to June 2011. Euro. Surveill. 2011; 16:198-89

26. Dundas S. et al. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin. Infect. Dis. 2001; 33: 923-931

27. Fukushima H. et al. Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City., 1996. Pediatr. Int. 1999;41: 213-217

28. Trofa A.F., Ueno-Olsen H., Oiwa R., Yoshikawa M. Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus. Clin Infect Dis. 1999. 29:1303-1306

29. Conradi H. Uber Iosliche., durch asptische Autolyse erhaltene Giftstoffe vonRuhr- und Typhus-Bazillen. Dtsch Med Wochenschr 1903; 29:26-28

30. Bridgwater F.A., Morgan R.S., Rowson K.E., Wright G.P. The neurotoxin of Shigella shigae: morphological and functional lesions produced in the central nervous system of rabbits. Br J Exp Pathol. 1955; 36(5):447-453

31. Konowalchuk J., Speirs J.I., Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun. 1977;18(3):775-779

32. Konowalchuk J., Dickie N., Stavric S., Speirs J.I. Properties of an Escherichia coli cytotoxin. Infect Immun. 1978 May;20(2):575-577

33. van Setten P.A., Monnens L.A., Verstraten R.G. et al. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics., protein synthesis., and induction of cytokine release. Blood. 1996;88:174-183

34. O’Brien A.D., LaVeck G.D. Purification and characterization of a Shigella dysenteriae 1-like toxin produced by Escherichia coli. Infect Immun. 1983; 40:675-683

35. O’Brien A.O., Lively T.A., Chen M.E. et al. Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. Lancet. 1983; 26 (1):702

36. Scheutz F., Teel L.D., Beutin L et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J Clin Microbiol 2012. 50:2951-2963

37. Eklund M., Leino K., Siitonen A. Clinical Escherichia coli strains carrying stx genes: stx variants and stx-positive virulence profiles. J Clin Microbiol. 2002; 40(12):4585-4593

38. Persson S1., Olsen K.E., Ethelberg S., Scheutz F. Subtyping method for Escherichia coli shiga toxin (verocytotoxin) 2 variants and correlations to clinical manifestations. J Clin Microbiol. 2007;45(6):2020-2024

39. Fraser M.E., Cherney M.M., Marcato P. et al. Binding of adenine to Stx2., the protein toxin from Escherichia coli O157:H7. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006; 62:627-630

40. Bertin Y., Boukhors K., Pradel N. et al. Stx2 subtyping of Shiga toxin-producing Escherichia coli isolated from cattle in France: detection of a new Stx2 subtype and correlation with additional virulence factors. J Clin Microbiol. 2001: 3060-3065

41. Beutin L., Miko A., Krause G et al. Identification of human-pathogenic strains of Shiga toxin-producing Escherichia coli from food by combination of serotyping and molecular typing of Shiga toxin genes. Appl Environ Microbiol. 2007. 73: 4769-4775

42. Brett K.N., Ramachandram V., Hornitzky M.A. et al. Stx1c is the most common Shiga toxin 1 subtype among in Shiga toxin producing Escherichia coli 491 isolates from sheep but not among isolates from cattle. J Clin Microbiol. 2003; 41: 926-936

43. Gobius K.S., Higgs G.M., Desmarchelier P.M. Presence of activatable Shiga toxin genotype (stx2d) in Shiga toxigenic Escherichia coli from livestock sources. J Clin Microbiol. 2003; 41:3777-3783

44. Krüger A., Lucchesi P.A. Verotoxins in bovine and meat verotoxin-producing Escherichia coli isolates: type., number of variants., and relationship to cytotoxicity. Appl Environ Microbiol. 2011; 77:73-79

45. Linggood M.A., Thompson J.M. Verotoxin production among porcine strains of Escherichia coli and its association with edema disease. J Med Microbiol. 1987; 25: 359-362

46. Schmidt H., Scheef J., Morabito S. et al. A new shiga toxin 2 variant (Stx2f) from Escherichia coli isolated from pigeons. Appl. Environ Microbiol. 2000; 66., 1205-1208

47. Friesema I., van der Zwaluw K., Schuurman T. et al. Emergence of Escherichia coli encoding Shiga toxin 2f in human Shiga toxin- producing E. coli (STEC) infections in the Netherlands., January 2008 to December 2011. Euro Surveill. 2014; 19 (17): 26-32

48. Shimizu H., Field R.A., Homans S.W., Donohue-Rolfe A. Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. Biochemistry. 1998;37: 11078-11082

49. Ling H., Boodhoo A., Hazes B. et al. Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry. 1998;37:1777-1788

50. Sandvig K., Garred O., Prydz K. et al. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature. 1992; 6;358(6386):510-512

51. Endo Y., Tsurugi K., Yutsudo T. et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988; 15;171(1-2):45-50

52. Fraser M.E., Cherney M.M., Marcato P. et al. Binding of adenine to Stx2., the protein toxin from Escherichia coli O157:H7. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006; 62:627-630

53. Bielaszewska M., Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost. 2005;94:312-318

54. Muthing J., Schweppe C.H., Karch H., Friedrich A.W. Shiga toxins., glycosphingolipid diversity., and endothelial cell injury. Thromb Haemost. 2009;101:252-264

55. Richardson S.E., Karmali M.A., Becker L.E., Smith C.R. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol. 1988;19:1102-1108

56. Bitzan M., Richardson S., Huang C. et al. Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro. Infect Immun. 1994;62:3337-3347

57. Cooling L.L., Walker K.E., Gille T., Koerner T.A. Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid. Infect Immun. 1998;66:4355-4366

58. Ghosh S.A., Polanowska-Grabowska R.K., Fujii J. et al. Shiga toxin binds to activated platelets. J Thromb Haemost. 2004;2:499-506

59. Karpman D., Papadopoulou D., Nilsson K. et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood. 2001;97:3100-3108

60. Te Loo D.M., Monnens L.A., van Der Velden T.J. et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood. 2000;95:3396-3402

61. Te Loo D.M., van Hinsbergh V.W., van den Heuvel L.P., Monnens L.A. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J Am Soc Nephrol. 2001;12:800-806

62. Louise C.B., Obrig T.G. Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin., interleukin-1 beta., and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun. 1991;59:4173-4179

63. van de Kar N.C., Monnens L.A., Karmali M.A., van Hinsbergh V.W. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood. 1992;80:2755-2764

64. Stahl AL., Sartz L., Nelsson A. et al. Shiga toxin and lipopoly-saccharide induce platelet-leukocyte aggregates and tissue factor release., a thrombotic mechanism in hemolytic uremic syndrome. PLoS One. 2009;4:e6990

65. Iordanov M.S., Pribnow D., Magun J.L. et al. Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol Cell Biol. 1997;17:3373-3381

66. Tesh V.L. Activation of cell stress response pathways by Shiga toxins. Cell Microbiol. 2012;14:1-9

67. Tesh V.L. Induction of apoptosis by Shiga toxins. Future Microbiol. 2010.5., 431-453

68. Zoja C., Buelli S., Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol. 2010; 25(11):2231-2240

69. Thurman J.M., Marians R., Emlen W. et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4(12):1920-1924

70. Morigi M., Galbusera M., Gastoldi S et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187:172-180

71. Orth D., Khan A.B., Naim A. et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182:6394

72. Ehrlenbach S., Rosales A. et al. Shiga Toxin 2 Reduces Complement Inhibitor CD59 Expression on Human Renal Tubular Epithelial and Glomerular Endothelial Cells. Infection and Immunity. 2013; 81(8): 2678-2680

73. Arvidsson I., Stâhl A.L. et al. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol. 2015; 1., 194(5): 2309-2318

74. Stahl A.L., Sartz L., Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood. 2011;117:5503-5513

75. Locatelli M., Buelli S., Pezzotta A. et al. Shiga Toxin Promotes Podocyte Injury in Experimental Hemolytic Uremic Syndrome via Activation of the Alternative Pathway of Complement. Journal of the American Society of Nephrology : JASN. 2014;25(8):1786-1798

76. Wong C.S., Jelacic S., Habeeb R.L. et al. The risk of haemolytic uraemic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Eng J Med. 2000; 342:1930-1936

77. Niaudet Р. Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) in children., Up To Date., 2015

78. Caillaud C., Zaloszyc A. et al. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol. 2016; 23;31(1):157-161

79. Fang C.J., Fremeaux-Bacchi V., Liszewski M.K. et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS)., fatal Stx-HUS., C3 glomerulonephritis., and the HELLP syndrome. Blood 2008;111:624-632

80. Paton J.C., Paton A.W. Pathogenesis and diagnosis of shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev. 1998; 11:450-479

81. Taranta А., Gianviti А. Genetic risk factors in typical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2009; 24: 1851-1857

82. Calderon Toledo C., Rogers T.J., Svensson M. et al. Shiga toxin-mediated disease in MyD88-deficient mice infected with Escherichia coli O157:H7. Am J Pathol. 2008; 173(5):1428-1439

83. Эмирова Х.М., Попа А.В., Козловская Н.Л. и соавт. Наследственная тромбофилия как фактор риска тяжелого течения гемолитико-уремического синдрома у детей. Педиатрия 2014 (2): 11-19

84. Buteau C., Proulx F. Leukocytosis in children with Escherichia coli O157:H7 enteritis developing the hemolytic-uremic syndrome. Pediatr Infect Dis J. 2000; 19(7):642-647

85. Tserenpuntsag B., Chang H-G et al. Hemolytic Uremic Syndrome Risk and Escherichia coli O157:H7. Emerging Infectious Diseases. 2005; 11 (12): 1955-1957

86. Wong C.S., Mooney J.C. et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis. 2012; 55(1):33-41

87. Nestoridi E., Kushak R.I., Duguerre D. et al.Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. Kidney Int. 2005; 67(6):2254-2266

88. Noris M., Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:1035-1050

89. Rahman R.C., Cobenas C.J., Drut R. et al. Hemorragic colitis in postdiarrheal hemolytic uremic syndrome: Retrospective analysis of 54 children. Pediat Nephrol 2012; 27:229-233

90. Ake J.A., Jelacic S., Ciol MAWatkins S.L. et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics. 2005; 115:673-680

91. Balestracci A., Martin S.M., Toledo I. et al. Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr Nephrol 2012; 27:1407

92. Зверев Д.В., Теблоева Л.Т. Почечная недостаточность. В: Таболина В.А., Бельмер С.В., Османов И.М., ред. Нефрология детского возраста. Медпрактика., М., 2005; 539-580

93. Зверев Д.В., Макулова А.И., Лифшиц В.И. и др. Выбор метода заместительной почечной терапии при острой почечной недостаточности у детей. Педиатрия 2007; 86(6):45-51

94. Лойманн Э., Цыгин А.Н., Саркисян А.А. Детская нефрология: практическое руководство. ЛигТерра., М., 2010; 184-193

95. Nathanson S., Kwon Th. Acute Neurological Involvement in Diarrhea-Associated Hemolytic Uremic Syndrome. Clin J Am Soc Nephrol. 2010; 5:1218-1228

96. Paton A.W., Paton J.C. Enterobacter cloacae producing a Shiga-like toxin II-related cytotoxin associated with a case of hemolytic-uremic syndrome. J Clin Microbiol. 1996;34(2):463-465

97. Garg A.X., Suri R.S., Barrowman N. et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review., meta-analysis., and meta-regression. JAMA. 2003;290: 1360-1370

98. Askiti V., Hendrickson K., Fish A.J. et al. Troponin I levels in a hemolytic uremic syndrome patient with severe cardiac failure. Pediatr Nephrol 2004; 19:345

99. de Buys Roessingh A.S., de Lagausie P., Baudoin V. et al. Gastrointestinal complications of post-diarrheal hemolytic uremic syndrome. Eur J Pediatr Surg 2007; 17:328

100. Suri R.S., Mahon J.L., Clark W.F. et al. Relationship between Esherichia coli O157:H7 and diabetes mellitus. Kidney Int Suppl. 2009. 112:44-46

101. Kaplan B.S., Meyers K.E., Schulman S.L. The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol. 1998; 9:1126-1133

102. Hermos C.R., Janineh M. Shiga Toxin-Producing Escherichia coli in Children: Diagnosis and Clinical Manifestations of O157:H7 and Non-O157:H7 Infection. Journal of clinical microbiology. 2011. 49(3):955-959

103. Romina J. Ferna'ndez-Brando., Leticia V. Bentancor et al. Antibody Response to Shiga Toxins in Argentinean Children with Enteropathic Hemolytic Uremic Syndrome at Acute and Long-Term Follow-Up Periods. PLoS ONE. 2011; 6., 4. - e19136

104. Bielaszewska M., Dobrindt U., Gärtner J. et al. Aspects of genome plasticity in pathogenic Escherichia coli. Int J Med Microbiol 2007;297:625-39

105. Hickey C.A., Beattie T.J., Cowieson J. et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 2011; 165:884

106. Niaudet P. Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) in children. Up to Date., 2015

107. Nitschke M., Sayk F., Härtel C et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 2012; 307:1046

108. Bell B.P., Griffin P.M., Lozano P. et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997; 100:E12

109. Siegler R., Oakes R. Hemolytic uremic syndrome., pathogenesis., treatment., and outcome. Curr Opin Paediatr., 2005; 17:200-204

110. Loirat C., Sonsino E., Hinglais N. et al. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 1988; 2:279

111. Rizzoni G., Claris-Appiani A., Edefonti A. et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988; 112:284

112. Slavicek J., Puretic Z., Novak M. et al. The role of plasma exchange in the treatment of severe forms of hemolytic-uremic syndrome in childhood. Artif Organs 1995; 19:506

113. Poolpol K., Orth-Höller D et al. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol. 2014 Mar;58(1):77-84

114. Delmas Y., Vendrely B., Clouzeau B. et al. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 2014; 29:565

115. Kemper M.J. Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol 2012; 27:161

116. Menne J., Nitschke M., Stingele R. et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345:e4565

117. Pape L., Hartmann H., Bange F.C. et al. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine (Baltimore) 2015; 94:e1000

118. McNeilly T.N., Mitchell M.C. et al. Immunization of cattle with a combination of purified intimin-531., EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge. Vaccine. 2010;28:1422-1428

119. Ritchie J.M.,Greenwich J.L. et al. An Escherichiacoli O157-specificengi- neeredpyocinpreventsandamelio- ratesinfectionby E. coli O157., H7 in ananimalmodelofdiarrhealdis- ease. Antimicrob. AgentsChemother. 2011; 55., 5469-5474

120. Trachtman H., Cnaan A., Christen E. et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003; 290:1337

121. Lopez E.L., Contrini M.M. et al. Safety and pharmacokinetics of urtoxazumab., a humanized monoclonal antibody., against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother. 2010;54:239-243

122. Smith M.J., Teel L.D. et al. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine. 2006b;24:4122-4129

123. Wahome P.G., Bai Y. et al. Identification of small-molecule inhibitors of ricin and shiga toxin using a cell-based high-throughput screen.Toxicon. 2010;56:526-534

124. Watanabe-Takahashi M., Sato T. et al. An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin. Infect Immun. 2010;78:177-183

125. Sandvig K., Bergan J. et al. Endocytosis and retrograde transport of Shiga toxin. Toxicon: 2009

126. Jandhyala D.M., Ahluwalia A. et al. a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression. Cell Microbiol. 2008;10:1468-1477

127. Ohara S., Kawasaki Y. et al. Role of vascular endothelial growth factor and angiopoietin 1 in renal injury in hemolytic uremic syndrome. Am J Nephrol. 2012;36(6):516-523

128. Obrig T.G., Karpman D. Shiga Toxin Pathogenesis: Kidney Complications and Renal Failure. Curr Top Microbiol Immunol. 2012 ; 357:105-136

129. Spinale J.M., Ruebner R.L. et al. Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr. 2013;25(2):203-208

130. Loos S., Ahlenstiel Th., Krany B., Markus J.K. An outbreak of shiga toxin-producing E.coli 0104:H4 HUS in Germany: presentation and short term outcome in children. Clinical Infectious Disease. 2012; 55(6):753-759

131. Magnus T., Röther J., Simova O. et al. Neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain. 2012;135(6):1850-1859

132. Tufro A., Arrizurieta E.E., Repeto H. Renal functional reserve in children with a previous episode of hemolytic uremic syndrome. Pediatr Nephrol 1991; 5:184-188

133. Caletti M.G., Missoni M., Vezzani C. Effect of diet., enalapril., or losartan in post-diarrheal hemolytic uremic syndrome nephropathy. Pediatr Nephrol 2001. 26:1247-1254

134. De Petris L., Gianviti A., Giordano U. et al. Blood pressure in the long-term follow-up of children with haemolytic uraemic syndrome. Pediatr Nephrol 2004; 19:1241-1244

135. Van Dyck M., Proesmans W. Renoprotection by ACE ingibitors after severe hemolytic uremic syndrome. Pediatr Nephrol 2003; 18: 688-690

136. Ferraris J.R., Ramirez J.A., Ruiz S. et al. Shiga toxin-associated hemolytic uremic syndrome: Absence of recurrence after renal transplantation. Pediatr Nephrol 2002. 17: 809-814